Market Overview

UPDATE: Bank of America Initiates Coverage on Myriad Genetics

Related MYGN
Edwards Lifesciences Raised to Buy - Analyst Blog
ImmunoGen, Inc. (IMGN) in Focus: Stock Rallies 11% - Tale of the Tape

According to a research report published this morning, Bank of America has initiated Myriad Genetics (NASDAQ: MYGN) with a Neutral rating and $28 PT.

Bank of America said in the report, "We reinstate Myriad Genetics (MYGN), a leading molecular diagnostics company, with a Neutral rating and $28 price objective. While we are positive about Myriad's initiatives to bolster near-to-midterm sales, we have some reservations about Myriad's long-term growth as its flagship product, BRACAnalysis, matures."

Myriad Genetics closed yesterday at $25.75.

Posted-In: Bank of AmericaAnalyst Color Initiation Analyst Ratings

 

Most Popular

Related Articles (MYGN)

Around the Web, We're Loving...

Partner Network

Get Benzinga's News Delivered Free